Cubist Systematic Strategies LLC acquired a new position in shares of Amarin Co. plc (NASDAQ:AMRN) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 64,610 shares of the biopharmaceutical company’s stock, valued at approximately $226,000.

Several other institutional investors have also bought and sold shares of the company. Westside Investment Management Inc. boosted its stake in shares of Amarin by 1.1% during the 2nd quarter. Westside Investment Management Inc. now owns 27,350 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 300 shares during the last quarter. State Street Corp lifted its stake in Amarin by 1.3% in the 2nd quarter. State Street Corp now owns 201,995 shares of the biopharmaceutical company’s stock valued at $814,000 after purchasing an additional 2,640 shares during the last quarter. Wells Fargo & Company MN lifted its stake in Amarin by 15.2% in the 2nd quarter. Wells Fargo & Company MN now owns 37,801 shares of the biopharmaceutical company’s stock valued at $152,000 after purchasing an additional 5,000 shares during the last quarter. Dynamic Technology Lab Private Ltd lifted its stake in Amarin by 94.2% in the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 87,104 shares of the biopharmaceutical company’s stock valued at $351,000 after purchasing an additional 42,246 shares during the last quarter. Finally, Stevens Capital Management LP acquired a new stake in Amarin in the 3rd quarter valued at about $229,000. Institutional investors own 40.12% of the company’s stock.

Several brokerages recently issued reports on AMRN. ValuEngine upgraded shares of Amarin from a “sell” rating to a “hold” rating in a research note on Saturday, November 4th. Zacks Investment Research downgraded shares of Amarin from a “hold” rating to a “sell” rating in a research note on Tuesday, December 12th. BidaskClub upgraded shares of Amarin from a “hold” rating to a “buy” rating in a research note on Friday, December 29th. Cantor Fitzgerald set a $10.00 target price on shares of Amarin and gave the company a “buy” rating in a research note on Thursday, January 4th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Amarin in a research note on Thursday, November 2nd. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $7.75.

Shares of Amarin Co. plc (NASDAQ AMRN) opened at $4.30 on Wednesday. Amarin Co. plc has a one year low of $2.81 and a one year high of $4.47. The stock has a market cap of $1,160.00, a PE ratio of -15.93 and a beta of 0.62. The company has a quick ratio of 1.32, a current ratio of 1.63 and a debt-to-equity ratio of -1.48.

Amarin (NASDAQ:AMRN) last issued its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The firm had revenue of $47.10 million during the quarter, compared to analyst estimates of $45.85 million. The company’s revenue for the quarter was up 45.4% on a year-over-year basis. During the same quarter last year, the business posted ($0.08) earnings per share. equities analysts predict that Amarin Co. plc will post -0.22 earnings per share for the current fiscal year.

In other Amarin news, insider Steven B. Ketchum sold 128,257 shares of the stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $4.25, for a total value of $545,092.25. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Steven B. Ketchum sold 64,683 shares of the stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $4.40, for a total transaction of $284,605.20. The disclosure for this sale can be found here. 3.72% of the stock is owned by corporate insiders.

WARNING: “Cubist Systematic Strategies LLC Takes Position in Amarin Co. plc (AMRN)” was published by Watch List News and is the property of of Watch List News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.watchlistnews.com/cubist-systematic-strategies-llc-takes-position-in-amarin-co-plc-amrn/1800781.html.

Amarin Company Profile

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Want to see what other hedge funds are holding AMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amarin Co. plc (NASDAQ:AMRN).

Institutional Ownership by Quarter for Amarin (NASDAQ:AMRN)

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.